BNC Korea Co., Ltd. (KOSDAQ:256840)

Market Cap	328.30B
Revenue (ttm)	99.34B
Net Income (ttm)	15.77B
Shares Out	68.39M
EPS (ttm)	233.23
PE Ratio	20.61
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	765,117
Average Volume	715,823
Open	4,960.00
Previous Close	4,970.00
Day's Range	4,750.00 - 4,970.00
52-Week Range	3,475.00 - 6,310.00
Beta	0.73
RSI	35.27
Earnings Date	Nov 14, 2025

About BNC Korea

BNC Korea Co., Ltd. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj., temporary reduce glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity; Juvegel, temporary reduce nasolabial folds in adults; Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia; HA fillers and skin booster fillers, including Cutegel, Cutegel Lidocaine, FLORE Lidocaine, CUTEGEL-M,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 251
• Stock Exchange: KOSDAQ
• Ticker Symbol: 256840

Financial Performance

In 2024, BNC Korea's revenue was 89.23 billion, an increase of 10.16% compared to the previous year's 81.00 billion. Earnings were 13.31 billion, a decrease of -48.19%.